[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bacterial-keratitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bacterial-keratitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100623255","intrastromal-moxifloxacin-as-an-adjunctive-therapy-in-recalcitrant-bacterial-keratitis-100623255",false,"NCT07394257","Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Clinical diagnosis of bacterial keratitis confirmed by corneal scraping and microbiology\n  * Recalcitrant keratitis defined as no significant clinical improvement after 48-72 hours of intensive topical antibiotic therapy\n  * Ability to provide written informed consent\n\nExclusion Criteria\n\n* Fungal, viral, or acanthamoeba keratitis\n* Corneal perforation or impending perforation\n* Known hypersensitivity to fluoroquinolones\n* Pregnancy or lactation\n* Immunocompromised state or current systemic immunosuppressive therapy\n* Previous intrastromal or intracameral antibiotic injection for the same episode","ALL","20 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","Bacterial keratitis is a potentially sight-threatening corneal infection that is commonly treated with intensive topical antibiotics. Despite appropriate therapy, some cases show inadequate clinical response, particularly when the infection involves the deep corneal stroma. Limited penetration of topical antibiotics into deeper corneal layers may contribute to treatment failure in these recalcitrant cases.\n\nIntrastromal antibiotic injection is a targeted drug-delivery approach that allows high local antimicrobial concentrations directly at the site of infection. Moxifloxacin is a broad-spectrum fluoroquinolone with proven efficacy in bacterial keratitis and favorable corneal tissue penetration. However, evidence regarding the clinical benefit and safety of intrastromal moxifloxacin as an adjunctive treatment remains limited.\n\nThis randomized controlled trial aims to evaluate the efficacy and safety of intrastromal moxifloxacin injection as an adjunct to standard topical moxifloxacin therapy compared with topical therapy alone in patients with recalcitrant bacterial keratitis. The primary outcome is time to complete clinical resolution of infection. Secondary outcomes include visual acuity improvement, ulcer healing rate, need for additional interventions, and treatment-related complications.",[25,26,27],"Bacterial Keratitis","Recalcitrant Infectious Keratitis","Corneal Ulcer","RECRUITING","2026-02-01",{"date":31,"type":32},"2026-02-06","ACTUAL",{"date":34,"type":32},"2025-10-01",{"date":36,"type":19},"2026-04-01",{"name":38,"class":39},"Minia University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100356239","phase-1-safety-and-effectiveness-of-the-pxl-platinum-330-system-for-corneal-cross-linking-100356239","NCT03918408","Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking","Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions","Inclusion Criteria:\n\nSubjects who have one or both eyes that meet criteria 1 \\& 2 and 1 or more of the following criteria will be considered candidates for this study.\n\n* 12 years of age or older\n* Evidence of progressive keratoconus (based on the discretion of the physician as evidenced by an increase in astigmatism, asymmetry, or worsening vision in the last 3 or more months)\n* Presence of central or inferior steepening.\n* Axial topography consistent with keratoconus\n* Presence of one or more findings associated with keratoconus such as:\n* Fleischer ring\n* Vogt's striae\n* Decentered corneal apex\n* Munson's sign\n* Rizzutti's sign\n* Apical Corneal scarring consistent with Bowman's breaks\n* Scissoring of the retinoscopic reflex\n* Crab-claw appearance on topography\n* Steepest keratometry (Kmax) value ≥ 47.20 D\n* I-S keratometry difference \\> 1.5 D on the Pentacam\u002FGalilei\u002FOrbscan\u002FCassini map or topography map\n* Posterior corneal elevation \\>16 microns\n* Thinnest corneal point \\\u003C485 microns\n* AvaGen (Avellino Labs) genetic testing keratoconus risk score of 67 or higher (high risk).\n* Signed written informed consent\n* Willingness and ability to comply with schedule for follow-up visits\n* For Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction:\n* Contact Lens Type Minimum Discontinuation Time:\n* Soft: 1 Week\n* Soft Extended Wear: 2 Weeks\n* Soft Toric: 3 Weeks\n* Rigid gas permeable: 2 Weeks per decade of wear\n* Scleral Lenses\n* Investigator Discretion \\[Discontinuation of scleral lenses not required unless there is clinical evidence of corneal hypoxia (e.g. corneal neovascularization) at time of screening\\]\n* Signed written informed consent\n* Willingness and ability to comply with schedule for follow-up visits\n\nExclusion Criteria (any of the following are reasons for exclusion):\n\n* Eyes classified as either normal or atypical normal on the severity grading scheme.\n* Corneal pachymetry at the screening exam that is \\\u003C330 microns at the thinnest point in the eye(s) to be treated.\n* Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example:\n* History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, acanthomeoeba, etc.)\n* Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure.\n* Pregnancy (including plan to become pregnant) or lactation during the course of the study\n* A known sensitivity to study medications\n* Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests.\n* Patients with active medical implants (e.g. cardiac pacemakers)'\n* Patients who are aphakic\u002F pseudophakic","12 Years","45 Years",{"count":51,"type":19},300,[53],"PHASE1","To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.",[56,25,57],"Keratoconus, Unstable","Ectasia of Cornea","2024-11-09",{"date":60,"type":32},"2024-11-12",{"date":62,"type":32},"2019-09-01",{"date":64,"type":19},"2030-12",{"name":66,"class":39},"Pacific Clear Vision Institute",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":20,"phases":77,"briefSummary":79,"conditions":80,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100550753","early-phase-1-novel-antisense-oligonucleotide-eye-drops-for-treating-antibiotic-resistant-bacterial-keratitis-100550753","NCT06451172","Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis","ASOTARI","Inclusion Criteria:\n\n* The results of antimicrobial susceptibility testing in patients with bacterial keratitis showed multidrug-resistant bacterial infections, and the existing commercial antibiotics could not effectively control the disease.\n* Age over 18 years.\n* No systemic immune eye disease.\n* Good eyelid structure and blink function.\n* Exists the potential of visual recovery by evaluation of ocular structure and function.\n* Subjects or their legal guardians voluntarily participate in this study, sign informed consent, good compliance and cooperation with follow-up visits.\n\nExclusion Criteria:\n\n* Lacrimal coating and blink function loss.\n* Schirmer's test result is less than 2mm for severe dry eye disease.\n* Pregnant and lactating women (pregnancy defined in this study as positive urine pregnancy test).\n* Currently is involved in clinical trials of other drugs or medical devices.\n* Active eye infection (including but not limited to: blepharitis, infectious conjunctivitis, sclerotitis, endophthalmitis) in target eye or contralateral eye within 30 days prior to enrollment.\n* Ocular surface malignant tumor.\n* A history of allergic reaction or allergy to sodium luciferin, allergy to protein products used for treatment or diagnosis, allergy to ≥ 2 drugs or non-drug factors, or current allergic disease.\n* current in an infectious disease requiring oral, intramuscular or intravenous administration.\n* Patients with systemic immune diseases.\n* Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant neoplasms).\n* Not effective contraception.\n* In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less than 100 mmhg.\n* In uncontrolled diabetes, fasting glucose is no less than 10.0umol\u002FL.\n* Renal insufficiency, serum creatinine is more than 133umol\u002FL.\n* Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by electrocardiogram).\n* Liver dysfunction, al ANINE aminotransferase and aspartate aminotransferase levels are higher than 80 IU\u002FL.\n* Platelet level is below 100,000 \u002FuL or above 450,000 \u002FuL.\n* Hemoglobin level is below 10.0g\u002FdL (male) or 9.0g\u002FdL (female).\n* No anticoagulant was used, prothrombin time is higher than 16s, and thrombin time of activated part is higher than 50s.\n* HIV infection (HIV-positive).\n* Subjects lack compliance with the study or the ability to sign informed consent.\n* There are currently signs of systemic infection, including fever and ongoing antibiotic treatment (in this study, systemic infection was defined as deviation from normal values of white blood cells, lymphocytes, and neutrophils on routine blood tests).\n* Administration of Glucocorticoids and other systemic immunosuppressive drugs.\n* The investigator judges other conditions unsuitable for the trial","18 Years",{"count":76,"type":19},20,[78],"EARLY_PHASE1","The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.",[25,81,82,83,84,85,86,87,88,89],"Antibiotic-resistant Bacteria","Infections, Bacterial","Corneal Diseases","Eye Diseases","Vision Disorders","Sensation Disorders","Blindness","Antisense Peptide Nucleic Acid","Antibacterial Therapy",[25,82,83,84],"2024-06-08",{"date":93,"type":32},"2024-06-11",{"date":95,"type":32},"2023-10-11",{"date":97,"type":19},"2026-10-31",{"name":99,"class":39},"Eye & ENT Hospital of Fudan University"]